It is no surprise that the demand for biotechnology professionals cannot be met by those trained in Canada alone. The institutions and companies in this sector require an abundant supply of qualified, skilled talent. To reach peak productivity in the years ahead, the industry will need to look to the large pool of scientists, researchers, technicians and others trained abroad—members of Canada’s vast and diverse immigrant population.
A Vancouver biotechnology company that has found a way to halt abnormal blood-cell growth to combat a range of disorders from leukemia to allergic reactions has scooped up $14.5 million US in venture capital funding from local and U.S. investors.
Toronto, Ontario – April 23, 2007 – Novadaq®Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems and image guided therapies for the operating room, announced today that it has entered into an asset purchase agreement to acquire certain business assets of Xillix Technologies Corp. (Richmond, British Columbia), including all of Xillix’s intellectual property, certain capital assets and inventory.
In a landmark study, researchers at the BC Cancer Agency have discovered that all blood stem cells are not created equal. The discovery adds another layer of understanding about the basic biology of blood stem cells, which may lead to improved treatments for leukemia patients.